CM-512

N/A

Report date: 2026/04/10 20:01:49

Base Information

Drug NameCM-512

Drug Alias NameCM512CM-512

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-IL13Anti-Thymic stromal lymphopoietin

TargetsInterleukin-13Thymic stromal lymphopoietin

Therapy Area/IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Chronic UrticariaDermatitis, Atopic +[9]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesKeymed Biosciences Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBelenos Biosciences Inc Chengdu Kangnuoxing Biopharma Inc Keymed Biosciences Co Ltd

Inactive CompaniesN/A

Active IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Chronic UrticariaDermatitis, Atopic +[9]

Inactive IndicationsN/A

Other Information

ATC CodeN/A